Faeth Therapeutics, Inc. (FTH)
Develops experimental cancer drugs targeting immune pathways and tumor growth mechanisms.
$29.13-0.00%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+182.1%
The outlook
FTH is trading well above its 50- and 200-day moving averages, with analysts offering a strong buy consensus. The stock sits about 72% of the way through its 52-week range, and the average analyst price target sits roughly 88% above the current price. Overall sentiment leans notably bullish based on available research coverage.
What’s behind the score
Analyst consensusStrong Buy — 1.1 avg of 8 analysts
Price trendAbove its 50- & 200-day averages
52-week range72% of the way from its 52-week low to high
Price targetAvg target +88% vs current price
Analyst price target
~12-month · 8 analysts$54.75average target+88.0% vs now
Now $29.13
Low $50.00High $60.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$750.9M
52-wk high
$37.90
52-wk low
$6.33
50-day avg
$21.80
200-day avg
$18.68
Trailing P/E
—